MYC and familial pancreatic carcinoma: Gu et al. [57] highlighted the role of H1-2 in promoting chemoresistance and epithelial-mesenchymal transition (EMT) in pancreatic cancer, mediated through the c-MYC signaling pathway, suggesting targeting H1-2 could improve therapeutic outcomes by reducing metastatic potential.